Maravai Lifesciences Completes Acquisition of Officinae Bio's DNA and RNA Business

MT Newswires Live

2025/02/24

Maravai Lifesciences Holdings (MRVI) said Monday that it completed the acquisition of Officinae Bio's DNA and RNA business.

The company said the deal combines Officinae Bio's AI-driven mRNA design platforms with Maravai's and TriLink BioTechnologies' expertise in drug substance manufacturing, offering customers advanced technologies designed to achieve efficient progression from mRNA sequence optimization to clinical testing and commercial manufacturing.

Davide De Lucrezia, chief executive officer of Officinae Bio, will continue to lead the Officinae Bio team, now part of Maravai's Nucleic Acid Production segment, it added.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2513729902"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2513729902\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2513729902?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513729902","market":"sh","top_or_hot":-1,"title":"Maravai Lifesciences Completes Acquisition of Officinae Bio's DNA and RNA Business","media":"MT Newswires Live","content":"<html><body><p> Maravai Lifesciences Holdings (MRVI) said Monday that it completed the acquisition of Officinae Bio's DNA and RNA business.</p><p>The company said the deal combines Officinae Bio's AI-driven mRNA design platforms with Maravai's and TriLink BioTechnologies' expertise in drug substance manufacturing, offering customers advanced technologies designed to achieve efficient progression from mRNA sequence optimization to clinical testing and commercial manufacturing.</p><p>Davide De Lucrezia, chief executive officer of Officinae Bio, will continue to lead the Officinae Bio team, now part of Maravai's Nucleic Acid Production segment, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maravai Lifesciences Completes Acquisition of Officinae Bio's DNA and RNA Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaravai Lifesciences Completes Acquisition of Officinae Bio's DNA and RNA Business\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-24 21:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Maravai Lifesciences Holdings (MRVI) said Monday that it completed the acquisition of Officinae Bio's DNA and RNA business.</p><p>The company said the deal combines Officinae Bio's AI-driven mRNA design platforms with Maravai's and TriLink BioTechnologies' expertise in drug substance manufacturing, offering customers advanced technologies designed to achieve efficient progression from mRNA sequence optimization to clinical testing and commercial manufacturing.</p><p>Davide De Lucrezia, chief executive officer of Officinae Bio, will continue to lead the Officinae Bio team, now part of Maravai's Nucleic Acid Production segment, it added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2513729902","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513729902","pubTimestamp":1740403763,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Maravai Lifesciences Holdings (MRVI) said Monday that it completed the acquisition of Officinae Bio's DNA and RNA business.The company said the deal combines Officinae Bio's AI-driven mRNA design plat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc.","BK4121":"生命科学工具和服务","BK4588":"碎股","BK4139":"生物科技","BK4109":"特种化学制品","BK4585":"ETF&股票定投概念","DNA":"Ginkgo Bioworks Holdings Inc.","RNA":"Avidity Biosciences, Inc.","BK4505":"高瓴资本持仓"},"translate_title":"Maravai Lifesciences完成对Officinae Bio DNA和RNA业务的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1,"MRVI":0.9,"DNA":1},"content_text":"Maravai Lifesciences Holdings (MRVI) said Monday that it completed the acquisition of Officinae Bio's DNA and RNA business.The company said the deal combines Officinae Bio's AI-driven mRNA design platforms with Maravai's and TriLink BioTechnologies' expertise in drug substance manufacturing, offering customers advanced technologies designed to achieve efficient progression from mRNA sequence optimization to clinical testing and commercial manufacturing.Davide De Lucrezia, chief executive officer of Officinae Bio, will continue to lead the Officinae Bio team, now part of Maravai's Nucleic Acid Production segment, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}